wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q37194640-58CB4E49-F302-4769-96D5-8E6404C85683
Q37194640-58CB4E49-F302-4769-96D5-8E6404C85683
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37194640-58CB4E49-F302-4769-96D5-8E6404C85683
Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
P2860
Q37194640-58CB4E49-F302-4769-96D5-8E6404C85683
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37194640-58CB4E49-F302-4769-96D5-8E6404C85683
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
9cadd3aeb50feeba0befa4ade775da0860f6b02e
P2860
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.